Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
life sciences
national blog main
6
×
boston blog main
boston top stories
san diego blog main
boston
clinical trials
national top stories
san diego top stories
startups
financing
gene therapy
new york blog main
san diego
san francisco blog main
third rock ventures
vc
20/20 healthcare partners
abide therapeutics
acetylon pharmaceuticals
allergan
ally bridge group
alnylam
ambys medicines
amgen ventures
amylin pharmaceuticals
amyotrophic lateral sclerosis
anthony despasqua
arena pharmaceuticals
artie suckow
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
ben cravatt
big data analytics
blackrock
bluebird bio
botox
What
diseases
6
×
medicines
new
biotech
develop
drug
drugs
genetic
ipo
raised
raises
therapeutics
treat
abide
advance
ago
aiming
ambys
analysis
appointed
associated
big
bio
biologics
biotechs
bring
chief
companies
company
considered
considering
control
data
deadly
deal
debuted
deliver
developing
device
dialysis
Language
unset
Current search:
diseases
×
biotech
×
" national blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?